Nuplazid FDA Approval History
FDA Approved: Yes (First approved April 29, 2016)
Brand name: Nuplazid
Generic name: pimavanserin
Dosage form: Tablets and Capsules
Company: Acadia Pharmaceuticals, Inc.
Treatment for: Parkinson’s Disease Psychosis
Nuplazid (pimavanserin) is a non-dopaminergic, selective serotonin inverse agonist (SSIA) for the treatment of psychosis associated with Parkinson’s disease.
Development Timeline for Nuplazid
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.